The system is designed to provide a minimally invasive treatment option for patients with symptomatic, severe aortic stenosis who are at high risk, or are ineligible, for open-heart surgery.

The study enrolled 50 patients with aortic valve disease who were implanted with the 21F CoreValve system in 2005 and 2006 at seven centers in Europe and Canada.

The study monitored patients through four years and found the CoreValve System maintained its structural integrity and led to positive clinical outcomes.